Current choroidal neovascularization treatment

Ophthalmologica. 2013;230(2):55-61. doi: 10.1159/000351660. Epub 2013 Aug 13.

Abstract

Purpose: This paper aims to describe the current situation of choroidal neovascularization (CNV) treatment.

Procedures: MEDLINE (2001-2013) was searched for original research studies (phase I, II, III), abstracts and review articles concerning CNV therapy, and other related articles. Selected information from related websites was also included.

Results: The management of CNV was developed through laser photocoagulation and photodynamic therapy, and has now evolved into anti-vascular endothelial growth factor (VEGF) use. Patients have achieved better visual acuity and toleration with the development of this therapy strategy. Combination therapy appears to offer a reduced retreatment frequency and long-term maintenance of the benefit with appropriate combination. Other treatment explorations with anti-inflammation and anti-VEGF are also ongoing.

Conclusions: Anti-VEGF monotherapy has become the first treatment for CNV patients. The investigation of other therapy strategies may prolong the interval of treatment and provide alternatives to CNV treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Choroidal Neovascularization / therapy*
  • Combined Modality Therapy
  • Humans
  • Laser Coagulation*
  • Photochemotherapy*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A